Search This Blog

Wednesday, August 14, 2019

Prevail Therapeutics EPS beats by $0.66

Prevail Therapeutics (NASDAQ:PRVL): Q2 GAAP EPS of -$0.58 beats by $0.66.
Cash and equivalents of $202.1M
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)